Skip to content

Effect of unani herb Marzanjosh in high cholesterol

Clinical Efficacy of Safoof Marzanjosh (Origanum majorana) in Hyperlipidemia - A Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075389
Enrollment
40
Registered
2024-10-16
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: safoof-e- marzanjosh: Preparation of test drug: The crude drug will be sent to drug testing laboratory for quality check.Then it is ground into fine powder and passed through No. 100 me

Sponsors

Firdhaus RUMANA K
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of Hyperlipidemia were identified with laboratory testing and having the values of plasma total cholesterol more than 200mg/dl, LDL-C less than 190 mg/dl, TG less than 499 mg/dl. Known cases of Hyperlipidemia with less than five years of disease history Known cases of type II Diabetes Mellitus, Hypothyroidism, obesity BMI less than 30 Age 30 to 60yrs and all gender.

Exclusion criteria

Exclusion criteria: Age less than 30 yrs and more than 60 yrs Pregnancy, Lactation Total Cholesterol more than 400 KNOWN HYPERTENSIVE CASES Systolic above 180 Diastolic above 110 mm Hg Malignancies, CAD, TB, AIDS, and other comorbidities such as Ischemic Heart Disease, CCF etc.

Design outcomes

Primary

MeasureTime frame
reduction in lipid levelsTimepoint: Baseline,45th day

Secondary

MeasureTime frame
improvement in quality of lifeTimepoint: 45 days

Countries

India

Contacts

Public ContactDR.FIRDHAUS RUMANA. K

Arignar Anna Government Hospital of Indian Medicine

muskaan.m@gmail.com9841620486

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026